New drug cocktail aims to shrink Hard-to-Treat breast cancer
NCT ID NCT06756932
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- metastatic breast cancer whose disease has progressed after prior treatments. The main goals are to check safety and find the best dose, while also seeing if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-21447 (a Bcl-2 inhibitor) combined with fulvestrant and/or BGB-43395 (a CDK4 inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with HR+/HER2- metastatic breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 120 participants, focused on safety and dosing. It is too small and early to know if the combination will work or be safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, NSW 2298, Australia
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109-4433, United States
-
Fudan University Shanghai Cancer Centerpudong
RECRUITINGShanghai, Shanghai Municipality, 201321, China
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, WA 6009, Australia
-
Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-3907, United States
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, VIC 3000, Australia
-
Saint Vincents Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, NSW 2010, Australia
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310016, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
RECRUITINGGuangzhou, Guangdong, 510245, China
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, QLD 4575, Australia
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242-1009, United States
-
Western Health Sunshine Hospital
RECRUITINGSt Albans, Victoria, VIC 3021, Australia